Lung Allograft Rejection Gene Expression Observational (LARGO) Study
- Conditions
- Lung DiseaseGraft Rejection
- Interventions
- Other: Non-interventional
- Registration Number
- NCT00751309
- Lead Sponsor
- XDx
- Brief Summary
The objective of the LARGO Study protocol is to collect peripheral blood samples, select associated lung biopsy pathology slides, and clinical data from lung transplant recipients to perform molecular analyses in association with the study endpoints. The primary objective is to use gene expression profiling of peripheral blood mononuclear cells to differentiate between the absence and presence of acute cellular rejection. The secondary objectives are to use other genomic and proteomic technologies to analyze RNA and protein in blood samples in relation to related clinical conditions. The overall goal is to apply novel molecular insights in the development of non-invasive molecular diagnostic tests for lung transplantation.
- Detailed Description
LARGO is a prospective, multi-center, international observational study with participating centers in the United States, Canada and Europe. The target enrollment for study completion is 2,100 subjects.
At each study visit, blood specimens are collected from subjects, processed and stored in the sample archive, with corresponding patient information entered into the clinical database. The analysis plan for each study objective includes a defined sample selection protocol that stipulates the inclusion and exclusion criteria for both patients and samples, and also the required number of blood specimens for the molecular analyses to achieve statistical significance.
The diagnosis and treatment of acute cellular rejection remains a clinical management priority that is currently based on transbronchial biopsy. Gene expression profiling is a technology based on molecular biology that measures changes in the RNA levels of different genes expressed by circulating mononuclear cells in the peripheral blood. A key goal of the project is to use gene expression profiling to differentiate between the absence and presence of lung allograft acute cellular rejection, with the aim of using this novel information to develop a non-invasive diagnostic testing alternative.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2044
- Lung and heart-lung transplant recipients who consent to participate and have transbronchial biopsy at the enrolling center during the study period
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 Non-interventional Lung and heart-lung transplanted subjects.
- Primary Outcome Measures
Name Time Method The absence of histologic rejection and normal or unchanged allograft function. Scheduled clinic visit Allograft function as determined via pulmonary function tests. Scheduled clinic visit Rejection episodes of at least moderate histologic grade which resulted in treatment of the patient with additional corticosteroids, anti-T cell antibodies, or total lymphoid irradiation. Scheduled clinic visit Documented CMV infection by culture, histology, or PCR, and at least one clinical sign or symptom of infection. Scheduled clinic visit Obliterative Bronchiolitis diagnosed pathologically by biopsy or by a progressive decline in pulmonary function tests consistent with a diagnosis of Bronchiolitis Obliterans Syndrome (BOS). Scheduled clinic visit Infections other than CMV, e.g. bacterial, other viral, and fungal infections. Scheduled clinic visit
- Secondary Outcome Measures
Name Time Method All cause mortality. Scheduled clinic visit Rejection of mild to moderate histologic severity prompting augmentation of the patient's chronic immunosuppressive regimen. Scheduled clinic visit Graft Failure or Retransplantation. Scheduled clinic visit Lymphoproliferative disorder (aka post-transplant lymphoma). Scheduled clinic visit Allograft dysfunction during the study period. Scheduled clinic visit Rejection of mild to moderate severity with allograft dysfunction prompting plasmapheresis or a diagnosis of "humoral" rejection. Scheduled clinic visit
Trial Locations
- Locations (20)
Hospital for Sick Children
🇨🇦Toronto, Ontario, Canada
UCLA Division of Pulmonary and Critical Care
🇺🇸Los Angeles, California, United States
Washington University School of Medicine
🇺🇸St. Louis, Missouri, United States
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Stanford University School of Medicine
🇺🇸Stanford, California, United States
University of Pittsburgh
🇺🇸Pittsburgh, Pennsylvania, United States
University of Colorado
🇺🇸Aurora, Colorado, United States
Mayo Clinic Transplant Center
🇺🇸Jacksonville, Florida, United States
Medizinische Universität Wien
🇦🇹Vienna, Austria
University of California, San Francisco
🇺🇸San Francisco, California, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
University of Michigan Health Systems
🇺🇸Ann Arbor, Michigan, United States
St. Louis Children's Hospital
🇺🇸St. Louis, Missouri, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
University Hospital and Clinics
🇺🇸Madison, Wisconsin, United States
Columbia University College of Physicians and Surgeons
🇺🇸New York, New York, United States
Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
Freeman Hospital
🇬🇧High Heaton, Newcastle upon Tyne, United Kingdom
The Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
University of Washington Medical Center
🇺🇸Seattle, Washington, United States